Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer
Status:
Completed
Trial end date:
2014-10-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess pharmacodynamics and safety of JNJ-212082 in order to
select the recommended dose of JNJ-212082 for patients with castration resistant prostate
cancer.